Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Considers Coverage For GE’s Risk-Predictor Tool For Sudden Cardiac Death

This article was originally published in The Gray Sheet

Executive Summary

The Medicare agency says it is reconsidering a 2008 national noncoverage policy for GE Healthcare’s microvolt T-Wave alternans testing tool for evaluating risk of sudden cardiac death, and the potential need for an ICD. An alternative MTWA technique is already covered, but the company that makes that product is going out of business.

You may also be interested in...



CMS Allows Local Contractors Latitude For SCD Risk-Assessor

After cardiologists strongly urged CMS to support MWTA testing using the modified moving average method to determine if patients are at risk of sudden cardiac death, CMS left an opening for local Medicare contractors to decide on coverage rather than retaining a national non-coverage policy.

CMS Says No, Again, To Modified Moving Average T-Wave Alternans Testing

In a new proposed decision memo, CMS says it plans to confirm its existing national non-coverage policy on microvolt T-wave alternans diagnostic testing with the modified moving average method.

Competitors Push New Data In Coverage Battle For T-Wave Alternans Tests

Industry and physician stakeholders say CMS missed a key study in considering its coverage policy for noninvasive tests that help assess a patient's need for an implantable defibrillator. Competing test makers have different views on how the new data should be interpreted

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel